The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk's Kamogelo Mmako told Spotlight: "We have not publicly announced launch timing for Rybelsus or Wegovy in South Africa." After Semaglutide, Tirzepatide is probably the next best known ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

EU mid-market update: Trump adds Middle East tensions to macro picture as trade war keeps volatility high; Novo Nordisk rises ...

As per provisional closing, the S&P BSE Sensex, tumbled 312.53 points or 0.40% to 78,271.28. The Nifty 50 index fell 42.95 points or 0.18% to 23,696.30.

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...